A Journey with LGMD: From Protein Abnormalities to Patient Impact

Dimitra G. Georganopoulou, Vasilis G. Moisiadis,Firhan A. Malik,Ali Mohajer, Tanya M. Dashevsky, Shirley T. Wuu,Chih-Kao Hu

The Protein Journal(2021)

Cited 17|Views5
No score
Abstract
The limb-girdle muscular dystrophies (LGMD) are a collection of genetic diseases united in their phenotypical expression of pelvic and shoulder area weakness and wasting. More than 30 subtypes have been identified, five dominant and 26 recessive. The increase in the characterization of new genotypes in the family of LGMDs further adds to the heterogeneity of the disease. Meanwhile, better understanding of the phenotype led to the reconsideration of the disease definition, which resulted in eight old subtypes to be no longer recognized officially as LGMD and five new diseases to be added to the LGMD family. The unique variabilities of LGMD stem from genetic mutations, which then lead to protein and ultimately muscle dysfunction. Herein, we review the LGMD pathway, starting with the genetic mutations that encode proteins involved in muscle maintenance and repair, and including the genotype–phenotype relationship of the disease, the epidemiology, disease progression, burden of illness, and emerging treatments.
More
Translated text
Key words
Limb-girdle muscular dystrophy (LGMD),Calpainopathy—LGMD R1 (2A),Dysferlinopathy—LGMD R2 (2B),Sarcoglycanopathies—LGMD R3-6 (2C-2F),Dystroglycanopathies—LGMD R9 (2I),Anoctaminopathy—LGMD R12 (2L)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined